; (B) current and expected production capacity, in the United States and in foreign countries, of each critical medication, including the domestic and foreign capacity to surge production of each critical medication and the time required to do so, taking into account, among other things, current marketplace trends and factors and the economic viability of creating and maintaining such surge capacity in the absence of nonemergency commercial demand; (C) the potential demand and historic demand trends for each critical medication in the event of a public health emergency, including demand in the United States and in foreign countries; and (D) potential constraints on the timely manufacture and distribution of each critical medication in sufficient quantities for each portion of the United States where it is needed in the event of public health emergency, including constraints due to the unavailability or limited availability of such critical medication or any key ingredients thereof (including active pharmaceutical ingredients) from one or more foreign countries. (3) Conduct of evaluation In carrying out paragraph (1), the Secretary may consider such other factors as the Secretary considers relevant to determining the supply chain vulnerability of each critical medication and each key ingredient thereof (including active pharmaceutical ingredients) in the event of a public health emergency, which may include— (A) whether and to what extent the existing sources of such supply for the United States are domestic or foreign, the specific foreign countries from which any such foreign supply is obtained and in what quantities, and the extent of the risk of a disruption in supply from each such foreign country in the event of a public health emergency